Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art
- 1 January 2018
- journal article
- review article
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 17, 8-12
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Emerging trends in the immunotherapy of pancreatic cancerCancer Letters, 2018
- Advances on immunotherapy in genitourinary and renal cell carcinomaTranslational Cancer Research, 2017
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Engineering Therapeutic T Cells: From Synthetic Biology to Clinical TrialsAnnual Review of Pathology: Mechanisms of Disease, 2017
- Immunotherapy in genitourinary malignanciesCurrent Opinion in Urology, 2016
- Targeting the T-Cell Co-stimulatory CD27/CD70 Pathway in Cancer Immunotherapy: Rationale and PotentialImmunotherapy, 2015
- Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate CancerBioDrugs, 2015
- Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular ImmunotherapyInternational Reviews of Immunology, 2015
- T-cell therapy at the thresholdNature Biotechnology, 2012